{"nctId":"NCT00523978","briefTitle":"A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation","startDateStruct":{"date":"2006-10"},"conditions":["Paroxysmal Atrial Fibrillation"],"count":245,"armGroups":[{"label":"Experimental","type":"EXPERIMENTAL","interventionNames":["Device: Arctic Front® Cryoablation Catheter"]},{"label":"Control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Flecainide or Sotalol or Propafenone"]}],"interventions":[{"name":"Arctic Front® Cryoablation Catheter","otherNames":["Arctic Front® Cardiac CryoAblation Catheter System","Artic Front®"]},{"name":"Flecainide or Sotalol or Propafenone","otherNames":["Tambocor","Sotalol","Propafenone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented Paroxysmal Atrial Fibrillation (PAF): PAF diagnosis, 2 episodes of PAF within the last 2 months, at least 1 episode of PAF must be documented\n* Age 18-75\n* Documented Effectiveness Failure of one (1) AF drug\n* Willing to be randomized to either group and do full 12 month follow-up\n* Able to follow standardized AF drug protocol\n\nExclusion Criteria:\n\n* Any cardioversion within 3 months or more than 2 within 2 years\n* Amiodarone within 6 months\n* LA size \\> 5.0cm\n* Previous LA ablation/surgery, structural heart disease, heart failure class III or IV\n* Hypertrophic cardiomyopathy, Mitral prosthesis\n* Unstable angina, uncontrolled hyperthyroidism\n* Stroke or TIA within 6 months, MI within 2 months, cardiac surgery within 3 months\n* Thrombocytosis, thrombocytopenia\n* Any condition contraindicating chronic anticoagulation\n* EF \\<40%\n* Pregnancy\n* Life expectancy \\<1year","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Acute Procedural Success (APS)","description":"Acute Procedural Success was defined as a demonstration of electrical isolation in ≥ 3 Pulmonary Veins (PVs) at the conclusion of the first protocol-defined cryoablation procedure. APS was decided at the end of the procedure the mean time was calculated for the time frame.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null}]}]}]},{"type":"PRIMARY","title":"Freedom From Chronic Treatment Failure (CTF)","description":"Subjects that did not have or were free of CTF. CTF was defined as the occurence of an Atrial Fibrillation (AF) intervention, use of non-study AF drug therapy, or the occurence of detectable AF which is is defined as an episode of AF, documented in a tracing, and lasting more than 30 seconds, occurring during a Non Blanked Follow-up Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Treatment Success","description":"Treatment Success was defined as Acute Procedure Success (APS) and freedom from Chronic Treatment Failure (CTF) for Experimental Subjects, and freedom from CTF for Control Subjects. Under this pre-specified definition of Treatment Success, Experimental Subjects must have had APS and remained free of CTF during the 12-month follow-up duration, while Control Subjects must have remained free of CTF during the 12-month follow-up duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Freedom From Major Atrial Fibrillation Events (MAFEs)","description":"Subjects that did not have or were free of MAFEs. MAFEs were serious adverse events categorized as cardiovascular death, myocardial infarction, stroke, or hospitalization for AF recurrence/ablation, flutter ablation, embolic events, heart failure, hemorrhage or anti-arrhythmic drug treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"PRIMARY","title":"Cryoablation Procedure Events (CPEs)","description":"Subjects that had CPEs. CPEs were device- or procedure-related serious adverse events (SAE) categorized as access site complications, cardiac damage, pulmonary vein (PV) stenosis, embolic complications, arrhythmias, unresolved phrenic nerve palsy and death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":163},"commonTop":["Atrial Fibrillation","Atrial Flutter","Headache","Cough","Dizziness"]}}}